Gary Pollack
Document Actions
1. Pharmacokinetics as an Interface Between Neuropharmacology and Physiological Psychology. Department of Psychology, Knox College, Galesburg, IL, October, 1984.
2. Influence of Thermal Injury on the Disposition of Antipyrine and Indocyanine Green. School of Pharmacy, State University of New York at Buffalo, August, 1986.
3. Enterohepatic Recirculation of Valproic Acid in the Rat. College of Pharmacy, University of Georgia, Athens, GA, April, 1987.
4. Disposition of Valproic Acid in the Rat: Protein Binding, Nonlinear Elimination, and Enterohepatic Recirculation. College of Pharmacy, Wayne State University, Detroit, MI, March, 1988.
5. Pharmacokinetics and Pharmacodynamics of Valproic Acid in the Developing Rat. College of Pharmacy, University of Minnesota, Minneapolis, MN, April, 1989.
6. A Gas Chromatographic Assay for the Direct Determination of Methanol in Whole Blood. Seventh Health Effects Institute Annual Conference, Scottsdale, AZ, April, 1990.
7. Pharmacokinetics and Pharmacodynamics of Valproic Acid in the Developing Rat. School of Pharmacy, State University of New York at Buffalo, Amherst, NY, December, 1990.
8. Pharmacokinetics and Pharmacodynamics of Valproic Acid Analogs. College of Pharmacy, University of Minnesota, Minneapolis, MN, February, 1991.
9. Dose-Dependent Disposition of Methanol in the Rat. Eighth Health Effects Institute Annual Conference, Colorado Springs, CO, May, 1991.
10. Methanol Disposition in the Pregnant Rat. CIIT, Research Triangle Park, NC, March, 1992.
11. Kinetics of Serum-CNS Translocation of Valproic Acid in the Rat: Developmental Aspects and Potential Mechanisms. Marion Merrel Dow, Kansas City, Mo., July, 1992.
12. Toxicokinetics of Methanol in Pregnancy. ILSI Risk Sciences Institute Workshop on Health Effects of Alternative Fuels, Research Triangle Park, NC, September, 1992.
13. Disposition of Methanol in the Pregnant Rat After Intravenous and Oral Administration. Ninth Health Effects Institute Annual Conference, Monterey, CA, December, 1992.
14. Use of In Vivo Uterine Microdialysis to Assess Methanol Disposition in the Rat Fetal Environment. Ninth Health Effects Institute Annual Conference, Monterey, CA, December, 1992.
15. Effector Site-Mediated Pharmacokinetics. Southeastern Regional AAPS Meeting, Research Triangle Park, NC, April, 1993.
16. Methanol Disposition in the Rat During Inhalation Exposure. Tenth Health Effects Institute Annual Conference, Reston, VA, April, 1994.
17. Pharmacokinetic/Pharmacodynamic Complexities of Morphine. School of Pharmacy, Medical College of Virginia, Richmond, VA, April, 1997.
18. Role of the Liver in Limiting Oral Bioavailability of Peptides. American Chemical Society Meeting, Drugs and Formulations II. LaJolla, CA, October, 1997.
19. Factors Determining Peptide Clearance and Activity. Eighth North American ISSX Meeting, Hilton Head, SC, October, 1997.
20. Enterohepatic Cycling. Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, MA, November, 1997.
21. Modulation of Opioid Pharmacodynamics by P-Glycoprotein. Astra Research Centre Montreal, Montreal, Canada, May, 1998.
22. Use of Competitive Adsorption Techniques to Estimate Protein Binding. Southeastern Regional AAPS Meeting, Chapel Hill, NC, June, 1998.
23. Use of Preclinical Pharmacokinetics and In Vitro Models to Assess Problems of Poor Oral Bioavailability. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, July, 1998.
24. Hepatobiliary Transport: Model Systems for Predicting the Hepatic Uptake and Biliary Excretion of Drug Candidates. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, July, 1998.
25. Blood-Brain Barrier Efflux Transport. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, July, 1999.
26. Blood-Brain Barrier Efflux Transport. Praecis Pharmaceuticals Inc., Boston, MA, October, 1999.
27. Role of Nitric Oxide in Opioid Tolerance Development. Knox College, Galesburg, IL, October, 1999.
28. Blood-Brain Barrier Efflux Transport. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, June, 2000.
29. The Impact of P-glycoprotein-Mediated Transport on Pharmacokinetics and Pharmacodynamics. Pfizer Pharmaceutical Co., November, 2000.
30. In Vitro-In Vivo Correlates of Drug Disposition: Blood-Brain Barrier Transport and Protein Binding. Nobex Pharmaceuticals, Research Triangle Park, NC, December, 2000.
31. Efflux Transport at the Blood-Brain Interface: Implications for Drug Delivery and Pharmacologic Effect. Pharmacia, October, 2001.
32. Pharmacokinetic and Pharmacodynamic Implications of Blood-Brain Barrier Efflux Transport. Departments of Pharmacology and Bioengineering, University of Toledo, March 2002.
33. Blood-Brain Barrier Efflux Transport. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, June, 2002.
34. Influence of P-glycoprotein-Mediated Transport on Opioid Pharmacokinetics and Pharmacodynamics. Bristol-Myers Squibb, Wilmington, DE, July 2002.
35. Influence of Serum Protein Binding on Drug Bioavailability. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, June, 2003.
36. Clinical Significance of Pharmacokinetic Variability due to Transporters. PharmaConference 2003, Pontresina, Switzerland, August 2003.
37. Why We Question Dogma: Lessons Learned From Studying the Pharmacokinetic Implications of the Blood-Brain Barrier. State University of New York at Buffalo, Buffalo, NY, April, 2004.
38. Applications of Pharmacokinetics and Pharmacodynamics in Drug Development. Tec de Monterey, Mexico City, Mexico, May, 2004.
39. Drug Delivery to Central Nervous System Targets: Challenges and Opportunities. New York Academy of Sciences, New York City, April 2005.
40. Influence of Serum Protein Binding on Drug Bioavailability. Drew University, Madison, NJ, June, 2005.
41. Crossing the Great Divide: The Therapeutic Challenge of the Blood-Brain Barrier. Dickinson College, Carlisle, PA, October, 2005.
42. Influence of Serum Protein Binding on Drug Bioavailability. Drew University, Madison, NJ, June, 2006.
43. The ITS Teaching and Learning First Partners Program: Content Designed for the Digital Native. University of North Carolina Teaching and Learning with Technology Conference, Raleigh, NC, March, 2007.
2. Influence of Thermal Injury on the Disposition of Antipyrine and Indocyanine Green. School of Pharmacy, State University of New York at Buffalo, August, 1986.
3. Enterohepatic Recirculation of Valproic Acid in the Rat. College of Pharmacy, University of Georgia, Athens, GA, April, 1987.
4. Disposition of Valproic Acid in the Rat: Protein Binding, Nonlinear Elimination, and Enterohepatic Recirculation. College of Pharmacy, Wayne State University, Detroit, MI, March, 1988.
5. Pharmacokinetics and Pharmacodynamics of Valproic Acid in the Developing Rat. College of Pharmacy, University of Minnesota, Minneapolis, MN, April, 1989.
6. A Gas Chromatographic Assay for the Direct Determination of Methanol in Whole Blood. Seventh Health Effects Institute Annual Conference, Scottsdale, AZ, April, 1990.
7. Pharmacokinetics and Pharmacodynamics of Valproic Acid in the Developing Rat. School of Pharmacy, State University of New York at Buffalo, Amherst, NY, December, 1990.
8. Pharmacokinetics and Pharmacodynamics of Valproic Acid Analogs. College of Pharmacy, University of Minnesota, Minneapolis, MN, February, 1991.
9. Dose-Dependent Disposition of Methanol in the Rat. Eighth Health Effects Institute Annual Conference, Colorado Springs, CO, May, 1991.
10. Methanol Disposition in the Pregnant Rat. CIIT, Research Triangle Park, NC, March, 1992.
11. Kinetics of Serum-CNS Translocation of Valproic Acid in the Rat: Developmental Aspects and Potential Mechanisms. Marion Merrel Dow, Kansas City, Mo., July, 1992.
12. Toxicokinetics of Methanol in Pregnancy. ILSI Risk Sciences Institute Workshop on Health Effects of Alternative Fuels, Research Triangle Park, NC, September, 1992.
13. Disposition of Methanol in the Pregnant Rat After Intravenous and Oral Administration. Ninth Health Effects Institute Annual Conference, Monterey, CA, December, 1992.
14. Use of In Vivo Uterine Microdialysis to Assess Methanol Disposition in the Rat Fetal Environment. Ninth Health Effects Institute Annual Conference, Monterey, CA, December, 1992.
15. Effector Site-Mediated Pharmacokinetics. Southeastern Regional AAPS Meeting, Research Triangle Park, NC, April, 1993.
16. Methanol Disposition in the Rat During Inhalation Exposure. Tenth Health Effects Institute Annual Conference, Reston, VA, April, 1994.
17. Pharmacokinetic/Pharmacodynamic Complexities of Morphine. School of Pharmacy, Medical College of Virginia, Richmond, VA, April, 1997.
18. Role of the Liver in Limiting Oral Bioavailability of Peptides. American Chemical Society Meeting, Drugs and Formulations II. LaJolla, CA, October, 1997.
19. Factors Determining Peptide Clearance and Activity. Eighth North American ISSX Meeting, Hilton Head, SC, October, 1997.
20. Enterohepatic Cycling. Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, MA, November, 1997.
21. Modulation of Opioid Pharmacodynamics by P-Glycoprotein. Astra Research Centre Montreal, Montreal, Canada, May, 1998.
22. Use of Competitive Adsorption Techniques to Estimate Protein Binding. Southeastern Regional AAPS Meeting, Chapel Hill, NC, June, 1998.
23. Use of Preclinical Pharmacokinetics and In Vitro Models to Assess Problems of Poor Oral Bioavailability. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, July, 1998.
24. Hepatobiliary Transport: Model Systems for Predicting the Hepatic Uptake and Biliary Excretion of Drug Candidates. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, July, 1998.
25. Blood-Brain Barrier Efflux Transport. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, July, 1999.
26. Blood-Brain Barrier Efflux Transport. Praecis Pharmaceuticals Inc., Boston, MA, October, 1999.
27. Role of Nitric Oxide in Opioid Tolerance Development. Knox College, Galesburg, IL, October, 1999.
28. Blood-Brain Barrier Efflux Transport. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, June, 2000.
29. The Impact of P-glycoprotein-Mediated Transport on Pharmacokinetics and Pharmacodynamics. Pfizer Pharmaceutical Co., November, 2000.
30. In Vitro-In Vivo Correlates of Drug Disposition: Blood-Brain Barrier Transport and Protein Binding. Nobex Pharmaceuticals, Research Triangle Park, NC, December, 2000.
31. Efflux Transport at the Blood-Brain Interface: Implications for Drug Delivery and Pharmacologic Effect. Pharmacia, October, 2001.
32. Pharmacokinetic and Pharmacodynamic Implications of Blood-Brain Barrier Efflux Transport. Departments of Pharmacology and Bioengineering, University of Toledo, March 2002.
33. Blood-Brain Barrier Efflux Transport. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, June, 2002.
34. Influence of P-glycoprotein-Mediated Transport on Opioid Pharmacokinetics and Pharmacodynamics. Bristol-Myers Squibb, Wilmington, DE, July 2002.
35. Influence of Serum Protein Binding on Drug Bioavailability. Residential School of Medicinal Chemistry, Drew University, Princeton, NJ, June, 2003.
36. Clinical Significance of Pharmacokinetic Variability due to Transporters. PharmaConference 2003, Pontresina, Switzerland, August 2003.
37. Why We Question Dogma: Lessons Learned From Studying the Pharmacokinetic Implications of the Blood-Brain Barrier. State University of New York at Buffalo, Buffalo, NY, April, 2004.
38. Applications of Pharmacokinetics and Pharmacodynamics in Drug Development. Tec de Monterey, Mexico City, Mexico, May, 2004.
39. Drug Delivery to Central Nervous System Targets: Challenges and Opportunities. New York Academy of Sciences, New York City, April 2005.
40. Influence of Serum Protein Binding on Drug Bioavailability. Drew University, Madison, NJ, June, 2005.
41. Crossing the Great Divide: The Therapeutic Challenge of the Blood-Brain Barrier. Dickinson College, Carlisle, PA, October, 2005.
42. Influence of Serum Protein Binding on Drug Bioavailability. Drew University, Madison, NJ, June, 2006.
43. The ITS Teaching and Learning First Partners Program: Content Designed for the Digital Native. University of North Carolina Teaching and Learning with Technology Conference, Raleigh, NC, March, 2007.